Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Ended early

TherACCage Therapeutic Artificial Cells based on Molecular Cages for Glioblastoma Treatment

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
1 September 2023 to 31 August 2025
Status
Ended early
EU funding
€181k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101059267

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is still a major societal challenge, as reflected by the Horizon's Europe mission on cancer and the Europe's Beating Cancer Plan. In particular, despite great advances in cancer treatment in recent decades, glioblastoma multiform (GBM) - the most common malignant brain tumor - stills remains without an effective cure and patients die in a few months. Around 220000 people die annually worldwide from GBM and its incidence is expected to increase in Europe due to its aging population.

The standard treatment relies on the systemic administration of chemotherapeutics, which has limited efficacy and causes side effects. To overcome current limitations, TherACCage will develop artificial cells based on drug-loaded molecular cages as advanced nanosystems to tackle GBM. Such artificial cells will be equipped with processing machinery resulting in advanced biocompatible nanosystems with the ability to recognize biomarkers of the GBM microenvironment and induce responsive drug delivery in situ.

The project combines unique expertise of the main host lab (molecular cages: cage-like molecular architectures with an internal cavity), the candidate (nanotechnology and artificial cells) and a secondary lab (evaluation of novel anticancer therapies) to ensure fulfillment of objectives. In a first stage, the fellow will be trained in advanced organic chemistry for the synthesis of degradable drug-loaded molecular cages.

In a second stage, the assembly of artificial cells with molecular cages and their in vitro evaluation will be carried out. Finally, the fellow will carry out a secondment in a biological lab for the pre-clinical evaluation of the developed nanosystems. Importantly, the project will also allow the fellow to gain experience in patenting and tech transfer. Altogether, TheACCage will develop a new therapeutic technology and provide the fellow with complementary scientific and transferable skills with a significant impact toward an independent research career.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator
Fundacion De La Comunidad Valenciana Centro De Investigacion Principe FelipeValenciaSpainAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI